An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Latest Information Update: 14 Oct 2024
Price :
$35 *
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms WHO-SOLIDARITY-GERMANY
- 09 Oct 2024 Status changed to withdrawn prior to enrolment.
- 18 Jun 2021 Status changed from active, no longer recruiting to discontinued.
- 10 Nov 2020 New trial record